Lymphoma, Non-Hodgkin, Familial
|
0.390 |
Biomarker
|
disease |
BEFREE |
Six patients with human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma receiving chemotherapy (CT) with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus granulocyte colony-stimulating factor were sequentially monitored to study the effects of these treatments on their immunologic status (CD4 and CD8 cell counts) and on HIV plasma viremia.
|
8959247 |
1996 |
Lymphoma, Non-Hodgkin, Familial
|
0.390 |
Therapeutic
|
disease |
CTD_human |
High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
|
11911406 |
2002 |
Lymphoma, Non-Hodgkin, Familial
|
0.390 |
Biomarker
|
disease |
BEFREE |
CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma.
|
14979480 |
2004 |
Lymphoma, Non-Hodgkin, Familial
|
0.390 |
Biomarker
|
disease |
BEFREE |
AMD3100 (plerixafor), a small molecule that selectively inhibits the chemokine receptor CXCR4 is approved for mobilization in combination with G-CSF in patients with Non-Hodgkin's lymphoma and multiple myeloma.
|
27905003 |
2017 |
Lymphoma, Non-Hodgkin, Familial
|
0.390 |
Biomarker
|
disease |
BEFREE |
Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis in chemotherapy-induced febrile neutropenia among breast cancer and Non-Hodgkin's lymphoma patients under Taiwan's national health insurance system.
|
27491287 |
2017 |
Lymphoma, Non-Hodgkin, Familial
|
0.390 |
Biomarker
|
disease |
BEFREE |
Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.
|
29238988 |
2018 |
Lymphoma, Non-Hodgkin, Familial
|
0.390 |
Biomarker
|
disease |
BEFREE |
Prospective data on the use of granulocyte-colony-stimulating factor (G-CSF) in non-Hodgkin's lymphoma and its aggressive subtypes, including diffuse large B-cell lymphoma (DLBCL), are limited.
|
29171913 |
2018 |
Lymphoma, Non-Hodgkin, Familial
|
0.390 |
Biomarker
|
disease |
BEFREE |
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
|
29410180 |
2018 |
Lymphoma, Non-Hodgkin, Familial
|
0.390 |
Biomarker
|
disease |
BEFREE |
A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤70 kg.
|
29895931 |
2019 |
Lymphoma, Non-Hodgkin, Familial
|
0.390 |
Biomarker
|
disease |
BEFREE |
Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
|
31433700 |
2020 |